Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.
We recently published a list of 10 Stocks Skyrocketing Today. In this article, we are going to take a look at where Viking ...
Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...
Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...
Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern. The ...
Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing ...
In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $29.10, with a +1.46% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily gain ...
In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $29.10, with a +1.46% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0 ...
After Viking Therapeutics (VKTX) announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ...